Establishment Labs (ESTA) traded higher on Thursday after Stifel launched its coverage of the breast implant maker with a Buy rating and an $84 target, citing better-than-expected growth prospects in the breast augmentation market.
Is a global medical device company dedicated to improving women’s health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology.
This release also includes information about our expectations regarding Adjusted EBITDA on a forward-looking basis.
We also present Adjusted EBITDA which includes additional adjustments for items such as other non-cash charges, gains or losses on extinguishment of debt, share-based compensation, contract termination costs, changes in contingent considerations payable for business acquisitions, and foreign currency gains and losses.